Ebola Resource Center
Ebola Resource Center
March 23, 2015
3 min watch
Save

Video: NIAID Ebola vaccine well tolerated, immunogenic

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

WILMINGTON, Del. — Julie Ledgerwood, DO, of the National Institute of Allergy and Infectious Diseases' Vaccine Research Center, reviews progress on development of the cAd3-EBO vaccine, presented today at the New Technologies, New Vaccines 2015 conference.

Ledgerwood said that the recombinant vaccine, which was rapidly advanced into Phase 1 clinical evaluation, was well tolerated and demonstrated immunogenicity.

Disclosure: Ledgerwood reports no relevant financial disclosures.